safinamide has been researched along with Nervous System Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buchwalder, C; Devineau, A; Dullaghan, EM; Gealageas, R; Goebeler, V; Grierson, DS; Heller, M; Kim, CMJ; Putnins, EE; So, PPL; Surendradoss, J | 1 |
| Kh, R; Singh, D; Wasan, H | 1 |
1 review(s) available for safinamide and Nervous System Diseases
| Article | Year |
|---|---|
Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
Topics: Alanine; Animals; Anticonvulsants; Antiparkinson Agents; Benzylamines; Humans; Monoamine Oxidase; Nervous System Diseases; Parkinson Disease | 2021 |
1 other study(ies) available for safinamide and Nervous System Diseases
| Article | Year |
|---|---|
Development of Novel Monoamine Oxidase-B (MAO-B) Inhibitors with Reduced Blood-Brain Barrier Permeability for the Potential Management of Noncentral Nervous System (CNS) Diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood-Brain Barrier; Dogs; Drug Development; Humans; Madin Darby Canine Kidney Cells; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nervous System Diseases | 2018 |